Your event should be here ! To publish, manage, promote... To learn or to be formed ... Online registrations

Site language : English - Français
Ref : 33019
Event :12th World ADC San Diego - The Digital Edition

Dates :Monday October 11th, 2021 - Thursday October 14th, 2021

Location :Online (Internet, Videoconferencing, ...)

Type :Conference & Seminar - International audience

Accreditation :--


 

Further information

The hotly anticipates 12th World ADC San Diego -The Digital Edition is back for 2021 as the industry-leading comprehensive forum for the antibody drug conjugate field with a revitalized agenda and revamped speaker faculty to bring you all the latest intelligence from the ADC world.

From one approval to another, the ADC renaissance and reinvigorated pipelines has uncovered some key learnings and data. World ADC takes pride in curating the highest quality insights from the past 12 months globally that will equip you to optimize your ADC development programs for 2021 and beyond.

Bringing together 500+ ADC experts from pharma, biotech and academia, this unique forum masterfully combines a dynamic mix of formal presentations, audience discussions, panel discussions and organized networking and is the place to be to build the foundation for successful future collaborations.

Delving into the pioneering developments from early discovery through to manufacturing, these are 4 virtual days your team cannot afford to miss!

Time: 9:00 am - 6:00 pm

Prices:

Drug Developer - Conference Only (2 Day Pass): USD 2199.00,
Drug Developer - Conference + Seminar OR Workshop Day (3 Day Pass): USD 2798.00,
Drug Developer - Conference + Seminar and Workshop Day (4 Day Pass): USD 3397.00,
Solution Provider - Conference Only (2 Day Pass): USD 2899.00,
Solution Provider - Conference + Seminar OR Workshop Day (3 Day Pass): USD 3598.00,
Solution Provider - Conference + Seminar and Workshop Day (4 Day Pass): USD 4297.00,
Academic Provider - Conference Only (2 Day Pass): USD 1499.00,
Academic Provider - Seminar OR Workshop Day (3 Day Pass): USD 1998.00,
Academic Provider - Conference + Seminar and Workshop Day (4 Day Pass): USD 2497.00

URLs:

Website: https://go.evvnt.com/778922-0?pid=4319

Tickets: https://go.evvnt.com/778922-2?pid=4319

Brochure: https://go.evvnt.com/778922-3?pid=4319

LinkedIn: https://go.evvnt.com/778922-4?pid=4319

Twitter: https://go.evvnt.com/778922-5?pid=4319

Speakers: Ahmed Bassyouni, Independent Consultant, Amy Han, Solid Tumor Targeted Therapies and Commercial Disease Area Leader, Regeneron, Andreas Pahl, Chief Scientific Officer, Heidelberg Pharma, Andrew Philips, Director of Next Generation Drug Conjugates, AbbVie, Ann MacLaren, Executive Director, Translational Development, Triphase Accelerator, Anthony (Tony) Polverino, Executive Vice President, Early Development and Chief Scientific Officer, Zymeworks, Anton Rosembaum, Head of Regulated Bioanalysis and OMICS by LC-MS within Integrated Bioanalysis, AstraZeneca, Antonio Palumbo, MD Global Medical Expert, GlaxoSmithKline, Aubrey Morgart, ADC Patient, Audrey Bendelac, ADC Scientific Manager, Process Development, Sanofi, Ben-Quan Shen, Principal Scientist, Genentech, Brian Clark, Independant Consultant, GMP Consulting, Brian Mendehlson, Senior Director, Exelixis, Brian O’Mara, Associate Director - Downstream Process Development, Ambrx, Brian Safina, Vice President – Chemistry, Bolt Biotherapeutics, Chee Ng, Associate Professor and Research Investigator, University of Kentucky, Chet Bohac, Senior Medical Director, Macrogenics, Chris Scott, Professor - Pharmaceutical Biosciences, Queen’s University Belfast, Christian Behrenbruch, Managing Director and Chief Executive Officer, Telix Pharmaceuticals, Christine Knuehl, TBR Lead, Merck, Daisuke Okajima, Scientist, Preclinical Pharmacology, Oncology, Daiichi Sankyo, Daniel Custar, Associate Director - Drug Substance, Chemistry, Manufacturing and Controls, Mersana, David Lyon, Senior Fellow, Research Lonza Pharma and Biotech, Lonza, David Newman, Independent Consultant, Donald Mager, Professor and Vice Chair of Pharmaceutical Sciences, University at Buffalo, Dong Wei, Associate Director - Bioanalytical, Biomarker, Drug Metabolism and Pharmacokinetics, Takeda, Earl Albone, Senior Director, Biochemistry Discovery, Eisai, Ed Ha, Founding Principal Scientist - Antibody Drug Conjugates, AngieX, Emily Stevens, Medical Director of Tactical Biomarker Team, Seagen, Emmett Schmidt, Vice President, Clinical Research, Lead, External Collaborations, Oncology Early Development, Merck, Engin Ayturk, Director - Chemistry Manufacturing and Control Process Engineering and Bioconjugation, Mersana, Federico Riccardi Sirtori, Director, Head of NBE-DMPK Innovative Bioanalytics, Merck KGaA, Gail Lewis Philips, Senior Scientist, Discovery Oncology, Genentech, Ganapathy Sarma, Director - Chemistry, Bolt Biotherapeutics, Gang Yao, Director, Head of Novel Modalities R&D, MilliporeSigma, Germo Gericke, Senior Vice President - Research and Development and Chief Medical Officer, Advanced Accelerator Applications, Gilles Gallant, Senior Vice President, Global Head of Oncology Development, Oncology R&D, Daiichi Sankyo, Giorgio Salciarini, Senior Manager – Technical, Business Development, BSP Pharmaceuticals, Greg Thurber, Associate Professor, University of Michigan, Hillary Shcuessler, Scientific Leader, GlaxoSmithKline, Hirdesh Uppal, Vice President, Head of Development Sciences, CytomX, Jay Harper, Associate Director - Research Onocology, AstraZeneca, Jia He, Senior Research Analyst, Beacon Targeted Therapies, John Lambert, Independent Consultant, Attager Consulting, John Rolf, Director, Product Quality, Seagen, John Valliere Douglass, Associate Director, Seagen, Jun Tang, Senior Direcctor, Business Development, Henlius, Justin Oh, Chief Business Officer, AbTis, Leo Nicacio, Vice President - Clinical Development, Seagen, Lisa Mcdermott, Director - Process, Analytical Development and Senior Manager, Millipore Sigma, Louie Namouvski, Group Medical director, AbbVie, Marc Damelin, Vice President, Biology, Mersana, Marie Zhu, Chief Technology Officer, Remegen, Martha Neagu, Associate Medical Director - Physician Development Program, AbbVie, Martyn Ryder, Director, ILC Dover, Megan O’Meara, Vice President, Head of Early Stage Development, Seagen, Michael J. Roberts, Scientific Consultant, NOF America Corporation, Mingchao Kang, Project Leader, EuCode, Ambrx, Minmin Qin, Senior Vice President of CMC, Miracogen, Naresh Jain, President and Chief Executive Officer, NJ Bio, Nathan Tumey, Assistant Professor, Pharmaceutical Sciences, Binghamton University, Neil Bander, Professor, Bernard and Josephine Chaus Chair in Urological Oncology, and Director of Urological Oncology Research, Weill Cornell Medicine, Nicola Stagg, Senior Scientist - Toxicologist and Toxicology Oncology Therapeutic Area Lead, Genentech, Patrick Groothuis, Principal Scientist - In Vivo Pharmacology, Toxicology, Drug Metabolism and Pharmacokinetics, Byondis, Paul Song, Chief Scientific Officer, Genequantum, Philip Howard, Chief Scientific Officer, Spirogen, Prathap Mahalingaiah, Senior Scientist - Research, Investigative Toxicology, Pathology and Global Preclinical Safet, Abbvie, Puja Sapra, Vice President, Head of Tumor Targeted Delivery, Oncology R&D, AstraZeneca, Rakesh Dixit, President and Founder, Bionavigen, Raphael Eric, Steiner Assistant Professor in the Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Rob Straubinger, Professor of Pharmaceutical Sciences, University at Buffalo, Robert Herbst, Executive Director – Technical Operations, ImmunoGen, Robert Lutz, Chief Science Officer, Iksuda, Robert Sussman, Managing Director, SafeBridge Regulatory and Life Sciences Group, Roger Beerli, Chief Scientific Officer, NBE-Therapeutics, Rolf Werner, Chief Operation Officer, Genequantum Healthcare Co Ltd, Ruud Coumans, Project Leader Antibody-Drug Conjugates, Byondis, Sabra Hanspal, Senior Scientist, AbbVie CMO, Scott Patterson, Vice President, Technical Support, ILC Dover, Scott Tagawa, Professor of Medicine and Professor of Medicine in Urology, Weill Cornell Medicine, Sean Smith, Executive Director of Chemistry, Silverback Therapeutics, Seema Kantak, Vice President, Biologics and Biotherapeutics, Exelixis, Sudhir Penugonda, Medical Director, Oncology Early Development, AbbVie, Sukumar Sakamuri, Vice President, Head of Chemistry, Ambrx, Susan Clardy, Senior Scientist - Analytical Chemistry, Manufacturing and Control, Mersana, Tae Kyo, Park Chief Executive Officer, Intocell, Tim Lowinger, Chief Scientific Officer, Mersana, Ty Davis, Investigator, GlaxoSmithKline, Valerie Odegard, President and Chief Scientific Officer, Silverback Therapeutics, Victor Yip, Principal Scientific Researcher, Genentech, Viola Chen, Senior Medical Director, Oncology, Merck, Violet Lee, Scientist, Genentech, Xinfang Li, Vice President - Process Development and Head of Chemistry, Manufacturing and Controls, Mabplex, Yutaka Matsuda, ADC Researcher, Ajinomoto Bio- Pharma Services, Yuyi Shen, Associate Director Process Development and Manufacturing, Bolt Biotherapeutics, Zhala Tawfig, Process Development and TT Associate Scientist, Ajinomoto Bio- Pharma Services
ior Scientist, AbbVie CMO, Scott Patterson, Vice President, Technical Support, ILC Dover, Scott Tagawa, Professor of Medicine and Professor of Medicine in Urology, Weill Cornell Medicine, Sean Smith, Executive Director of Chemistry, Silverback Therapeutics, Seema Kantak, Vice President, Biologics and Biotherapeutics, Exelixis, Sudhir Penugonda, Medical Director, Oncology Early Development, AbbVie, Sukumar Sakamuri, Vice President, Head of Chemistry, Ambrx, Susan Clardy, Senior Scientist - Analytical Chemistry, Manufacturing and Control, Mersana, Tae Kyo, Park Chief Executive Officer, Intocell, Tim Lowinger, Chief Scientific Officer, Mersana, Ty Davis, Investigator, GlaxoSmithKline, Valerie Odegard, President and Chief Scientific Officer, Silverback Therapeutics, Victor Yip, Principal Scientific Researcher, Genentech, Viola Chen, Senior Medical Director, Oncology, Merck, Violet Lee, Scientist, Genentech, Xinfang Li, Vice President - Process Development and Head of Chemistry, Manufacturing and Controls, Mabplex, Yutaka Matsuda, ADC Researcher, Ajinomoto Bio- Pharma Services, Yuyi Shen, Associate Director Process Development and Manufacturing, Bolt Biotherapeutics, Zhala Tawfig, Process Development and TT Associate Scientist, Ajinomoto Bio- Pharma Services

 

Further information

To access the information you need to be connected. Creating an account is easy and free!

Log to your account
Register on Doctorama

Details

12th World ADC San Diego - The Digital Edition Medicine - Pharmacy
adc, antibodydrugconjugate
Everyone
1000 -- --
English

Recommend this event